Treating Hypertension in the Patient With Overt Diabetic Nephropathy

Seminars in Nephrology

Volumn 27, Issue 2, 2007, Pages 182-194

  Lewis, Edmund J ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

angiotensin receptor blocker; angiotensin converting enzyme inhibitor; Diabetic nephropathy; diastolic blood pressure; hypertension; irbesartan; systolic good pressure

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; IRBESARTAN; LISINOPRIL; LOSARTAN; LOSARTAN POTASSIUM; RAMIPRIL; SPIRONOLACTONE; TRANDOLAPRIL; VERAPAMIL;

ALBUMINURIA; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; HUMAN; HYPERTENSION; MORTALITY; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION, RENAL; TREATMENT OUTCOME;

EID: 34047266573     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2007.01.005     Document Type: Article

References (57)

1. Kussman M.J., Goldstein H.H., and Gleason R.E. The clinical course of diabetic nephropathy. JAMA 236 (1976) 1861-1873
2. Mogensen C.E. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 285 (1982) 685-688
3. Nyberg D., Blohme G., and Norden G. Constant glomerular filtration rate in diabetic nephropathy. Acta Med Scand 219 (1986) 67-72
4. Parving H.H., Andersen A.R., Smidt U.M., et al. Early aggressive antihypertensive treatment reduces the rate of decline in kidney function in diabetic nephropathy. Lancet 1 (1983) 1175-1179
5. Parving H.H., Andersen A.R., Smidt U.M., et al. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ 294 (1987) 1443-1447
6. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ 317 (1998) 703-713
7. Lewis J.B., Berl T., Bain R.P., et al. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Am J Kidney Dis 34 (1999) 809-817
8. Lewis E.J., Hunsicker L.G., Clarke W.R., et al., Collaborative Study Group. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
9. Brenner B., Cooper M.E., de Zeeuw D., et al., RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
10. Pohl M.A., Blumenthal S., Cordonnier D.J., et al. Independent and additive impact of blood pressure control and angiotensin 2 receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: clinical implications and limitations. J Am Soc Nephrol 16 (2005) 3027-3037
11. Cruickshank J.M., Thorp J.M., and Zacharias F.J. Benefits and potential harm of lowering high blood pressure. Lancet 1 (1987) 581-584
12. D'Agostino R.B., Belanger A.J., Kannel W.B., et al. Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction. The Framingham Study. BMJ 303 (1991) 385-389
13. Cruikshank J.M. Coronary flow reserve and the J curve relation between diastolic blood pressure and myocardial infarction. BMJ 297 (1988) 1227-1230
14. Kaplan N. J-curve not burned off by HOT study. Hypertension Optimal Treatment. Lancet 351 (1998) 1748-1749
15. Cruickshank J.M. The J curve lives. Lancet 339 (1992) 187
16. Samuelson O., Wilhelmsen L., Anderson O.K., et al. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. Results from the primary prevention trial in Goteborg, Sweden. JAMA 258 (1987) 1768-1776
17. Farnett L., Multrow C.D., Linn W.D., et al. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous?. JAMA 265 (1991) 489-495
18. Messerli F.H., Mancia G., Conti C.R., et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. Ann Intern Med 144 (2006) 884-893
19. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized control trial. JAMA 290 (2003) 2805-2816
20. Berl T., Hunsicker L.G., Lewis J.B., and Collaborative Study Group. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 138 (2003) 542-549
21. Berl T., Hunsicker L.G., Lewis J.B., et al., Collaborative Study Group. Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial. J Am Soc Nephrol 16 (2005) 2170-2179
22. Bakris G.L., Weir M.R., Shanifar S., et al. Effects of blood pressure level on progression of diabetic nephropathy. Arch Intern Med 163 (2003) 1555-1565
23. Osher E., Greenmen Y., Tordjman K., et al. Attempted forced titration of blood pressure to <130/85 mmHg in type 2 diabetic hypertensive patients in clinical practice: the diastolic cost. J Clin Hypertens 8 (2006) 29-34
24. Atkins R.C., Briganti E.M., Lewis J.B., et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 45 (2005) 281-287
25. DeZeeuw D., Remuzzi G., Parving H.H., et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65 (2004) 2309-2320
26. Lewis E.J., Hunsicker L.G., Bain R.P., et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 329 (1993) 1456-1462
27. Nelson R.G., Bennett P.H., Beck G.J., et al., Diabetic Renal Disease Study Group. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. N Engl J Med 335 (1996) 1636-1642
28. Yokoyama H., Tomonaga O., Hirayama M., et al. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia 40 (1997) 405-411
29. Keane W.F., Brenner B.M., deZeeuw D., et al., RENAAL Study Investigators. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 63 (2003) 1499-1507
30. Rossing P., Hommel E., Smidt U.M., et al. Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 42 (1993) 715-719
31. Strippoli G.F., Craig M., Deeks J.J., et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systemic review. BMJ 329 (2004) 828-832
32. Strippoli G.F., Craig M.C., Schena F.P., et al. Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression. J Am Soc Nephrol 17 (2006) S153-S155
33. Strauss M.H., and Hall A.S. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 114 (2006) 838-854
34. Tsuyuki R.T., and McDonald M.A. Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation 114 (2006) 855-860
35. Casas J.P., Chua W., and Loukogeorgakis S. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systemic review and meta-analysis. Lancet 366 (2005) 2026-2033
36. The Antihypertensive and Lipid-Lowering Treating to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA 288 (2002) 2981-2997
37. Levey A.S., and Uhlig K. Which antihypertensive agents in chronic kidney disease?. Ann Intern Med 144 (2006) 213-215
38. Rahman M., Pressel S., Davis B.R., et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 165 (2005) 936-946
39. Hollenberg N.K. Omission of drug dose information [letter]. Arch Intern Med 166 (2006) 368
40. Rahman M., Pressel S.L., and Davis B.R. Omission of drug information [letter]. Arch Intern Med 166 (2006) 368-369
41. Williams B. The renin-angiotensin system and cardiovascular disease: hope or hype?. J Renin Angiotensin Aldosterone Syst 1 (2006) 142-146
42. Svensson P., De Faire U., Sleight P., et al. Comparative effect of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 28 (2001) E28-E32
43. deZeeuw D., Remuzzi G., Parving H.H., et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110 (2004) 921-927
44. Ibsen H., Olsen M.H., Wacktell K., et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients. Losartan Intervention for Endpoints Reduction in Hypertension Study. Hypertension 45 (2005) 198-202
45. Rossing K., Schjoedt K.J., Jensen B.R., et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 68 (2005) 1190-1198
46. Azizi M., and Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type I receptor antagonists. Circulation 109 (2004) 2492-2499
47. Mogensen C.E., Neldam S., Tikkanen I., et al. Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321 (2000) 1440-1444
48. Rossing K., Christensen P.K., Jensen B.R., et al. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 25 (2002) 95-100
49. Jacobsen P., Andersen S., Rossing K., et al. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 17 (2002) 1019-1024
50. Jacobsen P., Andersen S., Jensen B.R., et al. Addictive effect of ACE inhibition and angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. J Am Soc Nephrol 14 (2003) 992-999
51. Jacobsen P., Andersen S., Rossing K., et al. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 63 (2003) 1874-1880
52. Rossing K., Jacobsen P., Pietraszek L., et al. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 26 (2003) 2268-2274
53. Andersen N.H., Poulsen P.L., Knudsen S.T., et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care 28 (2005) 273-277
54. Hollenberg N.K. Is there a pharmacologic basis for combination renin axis blockade. Kidney Int 68 (2005) 2901-2903
55. Schjoedt K.J., Rossing K., Juhl T.R., et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 68 (2005) 2829-2836
56. Epstein M., Williams G.H., Weinberger M., et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin JASN 1 (2006) 940-951
57. Jafar T.H., Stark P.C., Schmid C.H., et al., AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. Ann Intern Med 139 (2003) 244-253